AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Lunit to Present Abstracts on AI-Powered Precision Pathology at AACR 2019

April 1, 2019

ATLANTA--(BUSINESS WIRE)--Apr 1, 2019--Lunit, a leading medical AI startup that develops AI-powered diagnostic and therapeutic imaging biomarkers, today announced that two abstracts showcasing findings from its AI pathology research portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019. The meeting will be held March 29 – April 3, 2019, at the Georgia World Congress Center in Atlanta, Georgia.

The accepted abstracts feature results derived from AI analysis of diverse cancer types and also demonstrate how AI-powered identification/quantification of cancer tissue based on H&E-stained histology images, can be a potential prognostic & predictive biomarker for breast cancer. In one of the abstracts, high-risk patients, classified by Lunit’s AI, were around 5-times more likely to die than low-risk patients, based on overall survival. More remarkably, high-risk patients were 3 to 5-fold more likely to respond to adjuvant chemotherapy, based on disease-free survival and overall survival, respectively. These abstracts will be presented during AACR poster sessions on Monday and Tuesday, 1-2 April.

“In our journey of developing predictive biomarkers for lung and breast cancer, these abstracts mark the successful completion of the first phase of our research,” said Brandon Suh, CEO of Lunit. “It marks a meaningful milestone in cancer research aided by AI. We look forward to accelerating our research and development in AI analysis of cancer tissues.”

Lunit’s AI research in the field of pathology has been recognized to be world-leading in various occasions, ranked world #1 in both MICCAI TUPAC Challenge 2016 and CAMELYON 2017, ahead of competition like Microsoft and IBM.

Lunit had employed an AI software, Lunit SCOPE, a deep learning-based H&E image analyzing tool that had been vital in the AI analysis of cancer tissues and the study itself. Lunit SCOPE will be available for demonstration during AACR, at Lunit booth #1744. An online demonstration is available at https://scope.lunit.io/ (Runs on Chrome Web Browser only).

“The AI analysis of H&E stained slide images showed great potential in the prediction of response to adjuvant chemotherapy in breast cancer,” said Kyunghyun Paeng, Head of Precision Pathology at Lunit. “We are moving closer to developing predictive biomarkers in lung and breast cancer and we welcome research partners to join forces with us in this development.”

View source version on businesswire.com:https://www.businesswire.com/news/home/20190401005342/en/

CONTACT: Lunit

Jussarang Lee, Communications Manager

+82-10-4884-0827

julee@lunit.io

KEYWORD: UNITED STATES ASIA PACIFIC NORTH AMERICA GEORGIA SOUTH KOREA

INDUSTRY KEYWORD: TECHNOLOGY SOFTWARE OTHER TECHNOLOGY PHOTOGRAPHY HEALTH BIOTECHNOLOGY ONCOLOGY RESEARCH SCIENCE

SOURCE: Lunit Inc.

Copyright Business Wire 2019.

PUB: 04/01/2019 08:00 AM/DISC: 04/01/2019 08:00 AM

http://www.businesswire.com/news/home/20190401005342/en